Zealand Pharma — Maj 2022

[exitnu]

• Net result from Discontinued Operations Related to Restructuring: DKK -41.8 million / USD -6.2 million (DKK 0.0 million / USD 0.0 million in the first three months of 2021).
• Cash, cash equivalents, and marketable securities: DKK 1,123.2 million / USD 167.6 million as of March 31, 2022 (March 31, 2021: DKK 1,604.1 million / USD 252.9 million).

[exitnu]

404 Page

GlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.

(www.globenewswire.com)

[exitnu]

Financial guidance for 2022
On March 30, 2022 Zealand updated the guidance for net product revenue from the sales of commercial products to be DKK 115 million +/- 10%. This was a decrease of 120 million Danish kroner from the guidance issued on March 10, 2022. Combined sales of V-Go and Zegalogue in Q1 were 39.2 million Danish kroner and in line with the updated guidance.

[exitnu]

Net operating expenses in 2022 are expected to be DKK 1,000 million +/-10%. This is unchanged from our updated guidance issued on March 30, 2022 and is a decrease of DKK 200 million from the guidance issued on March 10, 2022.

[exitnu]

Ingen udmelding mht. de forventede indtægter i hele 2022.

[Svingtraderen]

tak, chef

[Svingtraderen]

[Svingtraderen]

susp guidance for omsætning i 2022 -

[Helge_LarsenPI-redaktør]

Q&A fredag d. 20. kl 15. Stil gerne spørgsmål til Adam allerede nu.

[Helge_LarsenPI-redaktør]

Zealand Pharma Q1: Stor omsktrukturering - mere fokus på RnD https://www.proinvestor.com/investornyt/823603/zealand-pharma-q1-stor-omsktrukturering-mere-fokus-pa-rnd

[exitnu]

Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q1 2022 Earnings Call Transcript:

Access to this page has been denied

px-captcha

(seekingalpha.com)

[exitnu]

• Matt Dallas - SVP and CFO
• Adam Steensberg - President and CEO
• Conference Call Participants
• Thomas Bowers - Danske Bank
• Joseph Stringer - Needham
• Lucy Codrington - Jefferies

[exitnu]

• Company Participants

[exitnu]

Needham Maintains Buy on Zealand Pharma, Lowers Price Target to $32

Needham analyst Joseph Stringer maintains Zealand Pharma with a Buy and lowers the price target from $42 to $32.

[exitnu]

Svarer ca. til kurs 229. Hvilket svarer til +219% oppe i forhold til gårsdagens lukkekurs i kurs 73,75

[exitnu]

Og Joseph Stringer var igennem på CC igår ...

[exitnu]

@Svingtraderen - Selvtak i øjenhøjde

[Lazubia]

Hvis jeg forstod ret dropper Zealand V-Go, som trods alt solgte for et hoejt tocifret millionbeloeb. Derudover stopper CFO Matt Dallas. Ikke gode nyheder. Nu maa vi daeleme haabe at Glepaglutide leverer.

[exitnu]

"The Company’s commercial operations have been restructured to pursue partnerships for Zegalogue, V-Go and the glepaglutide and dasiglucagon late-stage clinical portfolio."

Nej, Zealand P
harma vil indgå i udviklings- og/eller kommercielle partnerskaber.

[Lazubia]

Ja det er maaske rigtigt nok, men de rykker v-go over under revenue for discontinued operations imens zegalogue forbliver under continued operations. Forstaar det ikke helt.